Page 12 - Amniotic Portfolio - RV4 2020 w_ WP
P. 12

Eur Spine J (2009) 18:1202–1212                                                                1209


           Table 4 Scar indexes among groups (n = 8, mean ± SD)
           Group         1 week                       6 weeks                       12 weeks
                         Scar index (%)  P a  P b     Scar index (%)  P a   P b     Scar index (%)  P a   P b
           FAM           4.05 ± 0.31   1.00   0.00*   18.03 ± 7.55  0.04*   0.46    19.35 ± 5.87  0.01*   0.22
           CAM           3.90 ± 0.26   1.00   0.00*   11.23 ± 4.24  0.67    0.03*   11.45 ± 3.83  0.40    0.01*
           AFF           3.25 ± 0.26                   3.48 ± 0.60                   3.70 ± 0.73
           Non-treatment  9.37 ± 1.55                 26.78 ± 9.38                  28.43 ± 8.28
           a
             P value indicates treatment group versus AFF (positive control)
           b
             P value indicates treatment group versus non-treatment group (empty control); * \0.05
           group. Then, the scar indexes of CAM group increased  Table 5 Quantitative evaluation of newly formed bone among
           with 11.23 ± 4.24 and 11.45 ± 3.83% at 6 and 12 weeks,  groups (n = 8, mean ± SD)
           respectively, which were significantly lower than those of  Group  6 weeks        12 weeks
           non-treatment group (P \ 0.05). However, CAM group
                                                                         Bone area  P a  P b  Bone area  P a  P b
           showed no significant difference in comparison with AFF           2                  2
                                                                         (mm )              (mm )
           group (P [ 0.05). The scar indexes of FAM group were
           18.03 ± 7.55 and 19.35 ± 5.87% at 6 and 12 weeks,  FAM        8.80 ± 3.58 0.04* 1.00  8.50 ± 2.73 0.04* 1.00
           respectively. Although the scar indexes were mildly lower  CAM  9.78 ± 2.43 0.01* 1.00 10.07 ± 2.70 0.01* 1.00
           than those of non-treatment group (P [ 0.05), they were  AFF  3.28 ± 0.76        3.65 ± 0.83
           significantly higher than those of AFF group (P \ 0.05)  Non-  8.00 ± 1.70        10.55 ± 1.46
           (Table 4).                                           treatment
                                                              a
                                                                P value indicates treatment group versus AFF (positive control)
           Amount of newly formed bone                        b  P value indicates treatment group versus non-treatment group
                                                              (empty control); * \0.05
           After 6 weeks, the newly formed bone originated from the
           vertebral lamina was observed in FAM, CAM, and non-  contributing factor for a significant subset of patients suf-
           treatment groups, which gradually decreased the size of  fering from FBSS [3, 26, 27]. However, several authors
           laminectomy defects. In contrast, less newly formed bone  have reported that there are no important differences
           was visible in AFF group. The areas of newly formed bone  between symptomatic and asymptomatic patients in fibro-
           were   8.80 ± 3.58,  8.50 ± 2.73  and  9.78 ± 2.43,  sis demonstrated by computed tomography (CT) and
                          2
           10.07 ± 2.70 mm in FAM and CAM groups at 6 and     magnetic resonance imaging (MRI). They concluded that
           12 weeks, respectively. They were both significantly  the degree of fibrosis was not related to recurrent symp-
           higher than that of AFF group (P \ 0.05). However, there  toms following lumbar disc surgery [1, 23]. But at least
           was no significant difference between theses two groups  epidural scarring can make a reoperation much more dif-
           (P [ 0.05) (Table 5).                              ficult, increasing the risks of dural tears, and nerve root
                                                              injury. There is no way to predict the patients in whom
                                                              symptomatic epidural fibrosis will develop, and once it
           Discussion                                         occurs there is no effective treatment. The main reasons for
                                                              scar formation include epidural fat destruction, hematoma,
           The study demonstrates that CAM can be implanted as a  and paraspinal muscular fiber invasion. Regardless of the
           physical barrier to reduce epidural fibrosis and scar adhe-  exact mechanisms of epidural scar adhesion, the crucial
           sion without affecting wound healing. The results provide  issue is to prevent the fibroblasts from migrating into the
           evidence that CAM is a promising biomaterial to reduce  exposed dura in the early healing phase. The interposition
           epidural fibrosis for future clinical application.  of a physical barrier to limit cell migration is considered an
             The formation of postoperative epidural fibrosis is an  effective strategy to reduce scar formation [30].
           inevitable result of laminectomy. Although the relationship  In this study, AM is selected as a barrier for its bio-
           between epidural fibrosis and clinical symptoms of FBSS  compatibility, absorbability, and easy manipulation. It is
           has not been unequivocally proven, as many as 24% of all  hypothesized to reduce inflammation, inhibit vasculariza-
           FBSS cases may be attributed to epidural scar adhesion  tion, and limit or prevent adhesion [31]. After implantation
           [27].The mechanical tethering of nerve roots, or the dura,  of FAM and CAM, there was no evidence of inflammatory
           by the excessive formation of epidural fibrosis may be a  reactions at 1, 6, and 12 weeks postoperatively. Few


                                                                                                      123
   7   8   9   10   11   12   13   14   15   16   17